India pharma sector

India pharma sector News

US FDA finds quality, data issues at Dadra plant of Sun Pharma

Sun Pharma got Form 483 which is issued when investigators observe conditions they deem to be violations of US drug regulations.

‘Despite ban, motion sickness medicine buclizine being sold as appetite stimulant’

The findings have caused a public health activist to urge the Delhi High Court to direct the government to initiate “criminal” proceedings against the medicine’s manufacturer — Mankind Pharmaceuticals Ltd.

Advertising

Drugs and medical devices: ‘Price cap helped patients save around Rs 15,000 crore’

According to the estimates of the National Pharmaceutical Pricing Authority (NPPA), patients across the country have saved around Rs 15,000 crore under the government’s initiative of ensuring affordable, quality medicines for all, Minister of State for Chemicals and Fertilisers Mansukh L Mandaviya said in a statement.

Maharashtra Druggists’ body to pharma firms: ‘Refrain from unethical practices to boost sales’

The letter dated August 27, states that “we have come to know from reliable market sources that your company’s MR/manager comes in the month-end to complete primary target” and then this employee is “adjusting” by paying from his incentives/salary, which is “highly objectionable and warrant your immediate attention”.

Oxytocin: Drug regulator calls for ‘strict vigil’

CDSCO has also requested state drug regulators to sensitise its inspectorate staff “to keep strict vigil on manufacture, sale and distribution of Oxytocin in the country”.

Health Ministry body: Allow Oxytocin sale by private chemists

From September 1, only Karnataka Antibiotics & Pharmaceuticals, a public sector entity, would be permitted to manufacture and distribute Oxytocin.

Advertising

Health ministry’s expert panel for banning 343 fixed drug combinations

In December last year, the Supreme Court had directed the panel for a fresh review of safety, efficacy and therapeutic justification of 349 FDCs.

Donald Trump promises action on drug prices that may impact India

While not specifically mentioning any country, Trump said "The world as usual has taken advantage of the United States. They are setting prices in other countries and we are not. The drug companies frankly are getting away with murder."

US Apex court decisions show that patent concerns are misplaced: IPA

IPA said that country’s intellectual patent regime conforms to the WTO norms.

Indian pharma battles for generic riches

$100 billion worth of drugs are coming off patent over the next two years.

Advertising